Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVENET: Everolimus 5 mg vs 10 mg in Advanced NET
NCT06472388Phase 2Recruiting
- Sponsor
- A.C.Camargo Cancer Center
- Start
- Apr 2024
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of everolimus in neuroendocrine tumors (NETs) (2 arms), sponsored by A.C.Camargo Cancer Center. Primary endpoint: Progression-Free Survival Rate at 12 months. Started Apr 2024; status: recruiting.
02
Drugs
everolimus
03
Conditions
neuroendocrine tumors (NETs)
Beyond the preview
Go deeper on NCT06472388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06472388.